Mylan Inc.

Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS

Mylan Launches First Generic Version of Exelon Capsules in the U.K.

Mylan’s Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments

PITTSBURGH, December 1, 2011 - - Product also 'prequalified' by WHO as a second-line treatment option - Mylan Inc.

MORE..

PITTSBURGH and POTTERS BAR, England, October 25, 2011 - Mylan Inc.

MORE..

Older News

PITTSBURGH - Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has been selected by the Clinton HIV/AIDS Initiative (CHAI) under its UNITAID-funded projects as the primary supplier of five antiretroviral (ARV) drugs used in second-line HIV/AIDS treatment regimens.

MORE..